Pulse Biosciences, Inc.
PLSEHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jun 3, 2026
Scan Results
Daily timeframePulse Biosciences, Inc. operates as a novel bioelectric medicine company. With a market capitalization of $1.68B, it sits in small-cap territory. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians.
Market Cap
$1.68B
Beta
1.63
P/E (TTM)
—
P/E (Fwd)
-27.59
EPS (TTM)
$-1.10
EPS (Fwd)
$-0.88
ROE
-80.7%
ROA
-45.0%
Cash
$68.3M
Total Debt
$7.2M
Free CF
-$29.1M
52W Change
38.3%
Annual Financials
Cash vs Debt
With $68.3M in cash and $7.2M in debt, PLSE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$29.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -80.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $700K (2022) to $350K (2025), a 50% decline worth watching.
A beta of 1.63 means PLSE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pulse Biosciences, Inc. and its sector.